Palmitic acid

Palmitic acid
Product Name Palmitic acid
CAS No.: 57-10-3
Catalog No.: CFN99716
Molecular Formula: C16H32O2
Molecular Weight: 256.42 g/mol
Purity: >=98%
Type of Compound: Miscellaneous
Physical Desc.: Powder
Targets: TLR | IL Receptor | TNF-α | PKC | TGF-β/Smad | PI3K | PPAR | GSK-3 | NF-kB | JNK
Source: The herbs of Atractylodes macrocephala Koidz.
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Price: $30/20mg
Palmitic acid induces anxiety-like behavior in mice while increasing amygdala-based serotonin metabolism, it induces down-regulation of APOM expression, is mediated via the PPARβ/δ pathway. Palmitic acid induces degeneration of myofibrils and modulate apoptosis in rat adult cardiomyocytes. it also shows in vivo antitumor activity in mice. Palmitic acid is CNS mediated via PKC-theta activation, resulting in reduced insulin activity.
Inquire / Order: manager@chemfaces.com
Technical Inquiries: service@chemfaces.com
Tel: +86-27-84237783
Fax: +86-27-84254680

Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
  • Korean J. Medicinal Crop Sci.2021, 29(6):425-433
  • Talanta.2022, 249:123645.
  • Antibiotics.2022, 11(4), 510.
  • Universitat Stuttgart2022, opus-12200.
  • Int J Mol Sci.2020, 21(19),7070.
  • Mol Cell.2017, 68(4):673-685
  • Nutrients.2022, 14(16):3393.
  • Medicina (Kaunas).2020, 56(12):685.
  • Nutrients.2023, 15(3):753.
  • J Nat Med.2020, 74(3):550-560.
  • Linoleic acid

    Catalog No: CFN93168
    CAS No: 60-33-3
    Price: $30/20mg
    Oleic acid

    Catalog No: CFN94800
    CAS No: 112-80-1
    Price: $30/20mg
    9,16-Dioxo-10,12,14-octadecatrienoic acid

    Catalog No: CFN98082
    CAS No: 217810-46-3
    Price: Inquiry(manager@chemfaces.com)
    2-Hydroxytetracosanoic acid ethyl ester

    Catalog No: CFN99353
    CAS No: 124111-47-3
    Price: Inquiry(manager@chemfaces.com)
    Sodium houttuyfonate

    Catalog No: CFN90975
    CAS No: 1847-58-1
    Price: $50/20mg
    1,18-Octadecanediol

    Catalog No: CFN98401
    CAS No: 3155-43-9
    Price: Inquiry(manager@chemfaces.com)
    Decanedioic acid

    Catalog No: CFN99210
    CAS No: 111-20-6
    Price: $30/20mg
    4-Oxododecanedioic acid

    Catalog No: CFN98390
    CAS No: 30828-09-2
    Price: Inquiry(manager@chemfaces.com)
    trans-2-Tridecene-1,13-dioic acid

    Catalog No: CFN92762
    CAS No: 14811-82-6
    Price: Inquiry(manager@chemfaces.com)
    2-Pentadecenedioic acid

    Catalog No: CFN92761
    CAS No: 81588-35-4
    Price: Inquiry(manager@chemfaces.com)
    Diabetes. 2001 Sep;50(9):2105-13.
    Glucose and palmitic acid induce degeneration of myofibrils and modulate apoptosis in rat adult cardiomyocytes.[Pubmed: 11522678]
    Several studies support the concept of a diabetic cardiomyopathy in the absence of discernible coronary artery disease, although its mechanism remains poorly understood. We investigated the role of glucose and Palmitic acid on cardiomyocyte apoptosis and on the organization of the contractile apparatus.
    METHODS AND RESULTS:
    Exposure of adult rat cardiomyocytes for 18 h to Palmitic acid (0.25 and 0.5 mmol/l) resulted in a significant increase of apoptotic cells, whereas increasing glucose concentration to 33.3 mmol/l for up to 8 days had no influence on the apoptosis rate. However, both Palmitic acid and elevated glucose concentration alone or in combination had a dramatic destructive effect on the myofibrillar apparatus. The membrane-permeable C2-ceramide but not the metabolically inactive C2-dihydroceramide enhanced apoptosis of cardiomyocytes by 50%, accompanied by detrimental effects on the myofibrils. The Palmitic acid-induced effects were impaired by fumonisin B1, an inhibitor of ceramide synthase. Sphingomyelinase, which activates the catabolic pathway of ceramide by metabolizing sphingomyeline to ceramide, did not adversely affect cardiomyocytes. Palmitic acid-induced apoptosis was accompanied by release of cytochrome c from the mitochondria. Aminoguanidine did not prevent glucose-induced myofibrillar degeneration, suggesting that formation of nitric oxide and/or advanced glycation end products play no major role.
    CONCLUSIONS:
    Taken together, these results suggest that in adult rat cardiac cells, Palmitic acid induces apoptosis via de novo ceramide formation and activation of the apoptotic mitochondrial pathway. Conversely, glucose has no influence on adult cardiomyocyte apoptosis. However, both cell nutrients promote degeneration of myofibrils. Thus, gluco- and lipotoxicity may play a central role in the development of diabetic cardiomyopathy.
    Anticancer Res. 2002 Sep-Oct;22(5):2587-90.
    Antitumor activity of palmitic acid found as a selective cytotoxic substance in a marine red alga.[Pubmed: 12529968]
    In a previous report, we discussed an extract from a marine red alga, Amphiroa zonata, which shows selective cytotoxic activity to human leukemic cells, but no cytotoxicity to normal human dermal fibroblast (HDF) cells in vitro.
    METHODS AND RESULTS:
    In this study, we identified Palmitic acid, a selective cytotoxic substance from the marine algal extract, and investigated its biological activities. At concentrations ranging from 12.5 to 50 micrograms/ml, Palmitic acid shows selective cytotoxicity to human leukemic cells, but no cytotoxicity to normal HDF cells. Furthermore, Palmitic acid induces apoptosis in the human leukemic cell line MOLT-4 at 50 micrograms/ml. Palmitic acid also shows in vivo antitumor activity in mice. One molecular target of Palmitic acid in tumor cells is DNA topoisomerase I, however, interestingly, it does not affect DNA topoisomerase II,
    CONCLUSIONS:
    suggesting that Palmitic acid may be a lead compound of anticancer drugs.
    Metabolism. 2014 Sep;63(9):1131-40.
    The saturated fatty acid, palmitic acid, induces anxiety-like behavior in mice.[Pubmed: 25016520]
    Excess fat in the diet can impact neuropsychiatric functions by negatively affecting cognition, mood and anxiety. We sought to show that the free fatty acid (FFA), Palmitic acid, can cause adverse biobehaviors in mice that last beyond an acute elevation in plasma FFAs.
    METHODS AND RESULTS:
    Mice were administered Palmitic acid or vehicle as a single intraperitoneal (IP) injection. Biobehaviors were profiled 2 and 24 h after Palmitic acid treatment. Quantification of dopamine (DA), norepinephrine (NE), serotonin (5-HT) and their major metabolites was performed in cortex, hippocampus and amygdala. FFA concentration was determined in plasma. Relative fold change in mRNA expression of unfolded protein response (UPR)-associated genes was determined in brain regions. In a dose-dependent fashion, Palmitic acid rapidly reduced mouse locomotor activity by a mechanism that did not rely on TLR4, MyD88, IL-1, IL-6 or TNFα but was dependent on fatty acid chain length. Twenty-four hours after Palmitic acid administration mice exhibited anxiety-like behavior without impairment in locomotion, food intake, depressive-like behavior or spatial memory. Additionally, the serotonin metabolite 5-HIAA was increased by 33% in the amygdala 24h after Palmitic acid treatment.
    CONCLUSIONS:
    Palmitic acid induces anxiety-like behavior in mice while increasing amygdala-based serotonin metabolism. These effects occur at a time point when plasma FFA levels are no longer elevated.
    Biochem Biophys Res Commun. 2014 Feb 28;445(1):203-7.
    Palmitic acid suppresses apolipoprotein M gene expression via the pathway of PPARβ/δ in HepG2 cells.[Pubmed: 24508264]
    It has been demonstrated that apolipoprotein M (APOM) is a vasculoprotective constituent of high density lipoprotein (HDL), which could be related to the anti-atherosclerotic property of HDL.
    METHODS AND RESULTS:
    Investigation of regulation of APOM expression is of important for further exploring its pathophysiological function in vivo. Our previous studies indicated that expression of APOM could be regulated by platelet activating factor (PAF), transforming growth factors (TGF), insulin-like growth factor (IGF), leptin, hyperglycemia and etc., in vivo and/or in vitro. In the present study, we demonstrated that Palmitic acid could significantly inhibit APOM gene expression in HepG2 cells. Further study indicated neither PI-3 kinase (PI3K) inhibitor LY294002 nor protein kinase C (PKC) inhibitor GFX could abolish Palmitic acid induced down-regulation of APOM expression.
    CONCLUSIONS:
    In contrast, the peroxisome proliferator-activated receptor beta/delta (PPARβ/δ) antagonist GSK3787 could totally reverse the Palmitic acid-induced down-regulation of APOM expression, which clearly demonstrates that down-regulation of APOM expression induced by Palmitic acid is mediated via the PPARβ/δ pathway.
    Hepatology. 2007 Sep;46(3):823-30.
    Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes.[Pubmed: 17680645 ]
    Obesity and the metabolic syndrome are closely correlated with hepatic steatosis. Simple hepatic steatosis in nonalcoholic fatty liver disease can progress to nonalcoholic steatohepatitis (NASH), which can be a precursor to more serious liver diseases, such as cirrhosis and hepatocellular carcinoma. The pathogenic mechanisms underlying progression of steatosis to NASH remain unclear; however, inflammation, proinflammatory cytokines, and oxidative stress have been postulated to play key roles. We previously reported that patients with NASH have elevated serum levels of proinflammatory cytokines, such as interleukin-8 (IL-8), which are likely to contribute to hepatic injury.
    METHODS AND RESULTS:
    This study specifically examines the effect of hepatic steatosis on IL-8 production. We induced lipid accumulation in hepatocytes (HepG2, rat primary hepatocytes, and human primary hepatocytes) by exposing them to pathophysiologically relevant concentrations of Palmitic acid to simulate the excessive influx of fatty acids into hepatocytes. Significant fat accumulation was documented morphologically by Oil Red O staining in cells exposed to Palmitic acid, and it was accompanied by an increase in intracellular triglyceride levels. Importantly, Palmitic acid was found to induce significantly elevated levels of biologically active neutrophil chemoattractant, IL-8, from steatotic hepatocytes. Incubation of the cells with palmitate led to increased IL-8 gene expression and secretion (both mRNA and protein) through mechanisms involving activation of nuclear factor kappaB (NF-kappaB) and c-Jun N-terminal kinase/activator protein-1.
    CONCLUSIONS:
    These data demonstrate for the first time that lipid accumulation in hepatocytes can stimulate IL-8 production, thereby potentially contributing to hepatic inflammation and consequent liver injury.
    J Clin Invest. 2009 Sep;119(9):2577-89.
    Palmitic acid mediates hypothalamic insulin resistance by altering PKC-theta subcellular localization in rodents.[Pubmed: 19726875]
    Insulin signaling can be modulated by several isoforms of PKC in peripheral tissues.
    METHODS AND RESULTS:
    Here, we assessed whether one specific isoform, PKC-theta, was expressed in critical CNS regions that regulate energy balance and whether it mediated the deleterious effects of diets high in fat, specifically Palmitic acid, on hypothalamic insulin activity in rats and mice. Using a combination of in situ hybridization and immunohistochemistry, we found that PKC-theta was expressed in discrete neuronal populations of the arcuate nucleus, specifically the neuropeptide Y/agouti-related protein neurons and the dorsal medial nucleus in the hypothalamus. CNS exposure to Palmitic acid via direct infusion or by oral gavage increased the localization of PKC-theta to cell membranes in the hypothalamus, which was associated with impaired hypothalamic insulin and leptin signaling. This finding was specific for Palmitic acid, as the monounsaturated fatty acid, oleic acid, neither increased membrane localization of PKC-theta nor induced insulin resistance. Finally, arcuate-specific knockdown of PKC-theta attenuated diet-induced obesity and improved insulin signaling.
    CONCLUSIONS:
    These results suggest that many of the deleterious effects of high-fat diets, specifically those enriched with Palmitic acid, are CNS mediated via PKC-theta activation, resulting in reduced insulin activity.
    6-Hydroxywogonin

    Catalog No: CFN95009
    CAS No: 76844-70-7
    Price: $368/5mg
    Carasinol B

    Catalog No: CFN95042
    CAS No: 777857-86-0
    Price: $333/5mg
    Shancigusin I

    Catalog No: CFN95061
    CAS No: 1435488-35-9
    Price: Inquiry(manager@chemfaces.com)
    Glicoricone

    Catalog No: CFN95063
    CAS No: 161099-37-2
    Price: $318/5mg
    Mirificin-4'-O-glucoside

    Catalog No: CFN95091
    CAS No: 168035-01-6
    Price: $288/5mg
    ent-16beta,17-dihydroxy-9(11)-kauren-19-oic acid

    Catalog No: CFN95172
    CAS No: 55483-24-4
    Price: $318/10mg
    4,7-Didehydroneophysalin B

    Catalog No: CFN95317
    CAS No: 134461-76-0
    Price: $338/5mg
    Crepidiaside B

    Catalog No: CFN95432
    CAS No: 101921-35-1
    Price: $318/10mg
    11beta,13-Dihydrolactucin

    Catalog No: CFN95433
    CAS No: 83117-63-9
    Price: $318/10mg
    4-Methoxybenzoylacetic acid

    Catalog No: CFN95446
    CAS No: 13422-77-0
    Price: $318/5mg